- Home
- APM vs NBY Comparison
APM vs NBY Comparison
Compare APM & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- NBY
- Stock Information
- Founded
- APM 2010
- NBY 2000
- Country
- APM United Kingdom
- NBY United States
- Employees
- APM N/A
- NBY N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- NBY
- Sector
- APM Health Care
- NBY
- Exchange
- APM Nasdaq
- NBY Nasdaq
- Market Cap
- APM 4.0M
- NBY 3.3M
- IPO Year
- APM 2018
- NBY 2007
- Fundamental
- Price
- APM $0.74
- NBY $0.53
- Analyst Decision
- APM
- NBY Strong Buy
- Analyst Count
- APM 0
- NBY 1
- Target Price
- APM N/A
- NBY $0.85
- AVG Volume (30 Days)
- APM 69.7K
- NBY 77.8K
- Earning Date
- APM 12-27-2024
- NBY 11-07-2024
- Dividend Yield
- APM N/A
- NBY N/A
- EPS Growth
- APM N/A
- NBY N/A
- EPS
- APM N/A
- NBY N/A
- Revenue
- APM $431,378.00
- NBY $13,844,000.00
- Revenue This Year
- APM $157,729.10
- NBY N/A
- Revenue Next Year
- APM N/A
- NBY $26.04
- P/E Ratio
- APM N/A
- NBY N/A
- Revenue Growth
- APM N/A
- NBY 15.40
- 52 Week Low
- APM $0.46
- NBY $0.36
- 52 Week High
- APM $17.49
- NBY $10.15
- Technical
- Relative Strength Index (RSI)
- APM 41.12
- NBY 35.25
- Support Level
- APM $0.73
- NBY $0.52
- Resistance Level
- APM $0.78
- NBY $0.58
- Average True Range (ATR)
- APM 0.09
- NBY 0.03
- MACD
- APM 0.04
- NBY -0.00
- Stochastic Oscillator
- APM 64.47
- NBY 11.56
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.